Dexpanthenol

Evidence Level: L5

Predicted Indications: 7

Dexpanthenol

Pharmacist Assessment Report

Dexpanthenol: From Skin and Gastrointestinal Motility Conditions to Anorectal Stricture

One-Sentence Summary

Dexpanthenol is a provitamin of pantothenic acid, used for skin conditions and gastrointestinal motility problems such as paralytic ileus and gastroparesis. The TxGNN model predicts it may be effective for anorectal stricture, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it. The only trial in the broader list of predictions is a Phase 3 study linked to a different indication, exanthem.

Quick Overview

Item	Content
Original Indication	Paralytic ileus, intestinal obstruction, gastroparesis, atopic eczema, dermatitis, and other skin diseases (the India license records contain no approved indication text)
Predicted New Indication	Anorectal stricture
TxGNN Prediction Score	0.9972
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data
Number of Listed Products	5 (valid: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available. Based on known information, dexpanthenol is converted in the body to pantothenic acid, a precursor of coenzyme A. This pathway supports epithelial repair and wound healing, and dexpanthenol has also been used as a stimulant of gastrointestinal motility.

The original indications span skin disease and gut motility disorders, so a link to anorectal conditions is plausible. Mucosal healing and bowel function are both relevant to the anorectal region.

However, anorectal stricture is a fibrotic, structural problem. No data show that dexpanthenol benefits this type of condition, so the prediction remains unproven.

Other predictions with the same score range (all L5, Hold unless noted):

Imperforate anus: a congenital malformation that needs surgery. Dexpanthenol could at most support postoperative skin care.
Anal polyp: no clear mechanistic rationale. The prediction likely reflects network proximity to related indications.
Vulvar inverted follicular keratosis: an indirect link through keratotic skin conditions. The lesion is usually excised.
Proctitis: a plausible link through mucosal regeneration and anti-inflammatory effects, but unproven.
Punctate epithelial keratoconjunctivitis: a plausible link through corneal epithelial healing, which fits the ophthalmic gels marketed in India. No supporting trials were provided.
Exanthem: the only prediction with a trial (see below). It is rated L4 with a “Research Question” recommendation.

Clinical Trial Evidence

No clinical trials are registered for anorectal stricture (the top prediction).

For reference, one trial was found for the sixth-ranked prediction, exanthem:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01136005	Phase 3	Completed	160	Randomized double-blind trial of Bepanthen® cream versus cetomacrogol cream to prevent papulopustular eruption in patients receiving EGFR inhibitors. Results were not provided, so efficacy cannot be judged. The rash is drug-induced, so it is only indirectly related to exanthem in general.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
175586	Panthobic Gel	Tube of 5 gm Eye Gel	Not specified
201487	Softvisc Gel	Tube of 5 gm Ophthalmic Gel	Not specified
109659	IO-Panthe Ophthalmic Gel	Tube of 5 gm Ophthalmic Gel	Not specified
174290	Panthol-D Eye Gel	Tube of 5 gm Ophthalmic Gel	Not specified
121915	Lubrex-PM Eye Gel	Tube of 5 gm Eye Gel	Not specified

All five licenses are valid single-ingredient ophthalmic gels. No oral, rectal, or other topical dermatological forms are registered, which matters for any anorectal use.

Safety Considerations

Contraindications (from the knowledge graph, not label text): Hemophilia is listed as a contraindicated disease.
Drug Interactions: No interactions were found in the queried data.

Please refer to the package insert for other safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The anorectal stricture prediction rests on the model score alone (L5), with no trials or publications. The mechanism is only loosely plausible for a fibrotic, structural condition. The registered products in India are ophthalmic gels, which do not fit an anorectal route.

To proceed, the following is needed:

Detailed mechanism of action data
Package insert warnings and contraindications from the India regulator
A literature and trial search specific to anorectal stricture
Confirmation of the actual target condition and results of NCT01136005, to decide whether the exanthem or radiation/treatment-induced skin reaction direction (currently L4) deserves priority
A route and formulation assessment, since no rectal or suitable topical product is currently registered
Clarification of the hemophilia contraindication signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.